Roche claims midstage win for obesity injectable Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

#weightloss #obesity #drugdevelopment #Roche #obesityinjectable #phase2results #dualGIPGLP1agonist #phase3programme #CT388 #CarmotTherapeutics #BMI #GLP1directedmedicines #EliLilly #GIPGLP1activity #NovoNordisk #GLP1drug #obesitycategory #IQVIA #ZealandPharma
zurl.co/nATCt

The £279m trial starting in Greater Manchester that could affect thousands Up to 3,000 people will take part

#obesity #weightloss #weightlosstrial #GreaterManchester #weightlossjabs #weightlossmedication #realworldstudy #weightlossdrug #Mounjaro #GLP1drug #Tirzepatide #obesitytreatment #Zepbound #EliLilly #publichealth #cardiometabolicmedicine #weightrelatedhealthconditions
zurl.co/MmyhW

Lilly trumpets heart health data with Mounjaro Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.

#weightloss #weightlossmedications #obesity #Lilly #EliLilly #hearthealthdata #Mounjaro #tirzepatide #GLP1agonists #cardiovascularoutcomes #SURPASSCVOTtrial #dualGLP1GIPagonist #GLP1drug #MACE #heartattackprevention #strokeprevention #MACEendpoints #CVD #cardiometabolichealth
zurl.co/9w8Sk